Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel

American Heart Journal

Volumn 157, Issue 1, 2009, Pages 148.e1-148.e5

  Siller Matula, Jolanta M ^a   Spiel, Alexander O ^a   Lang, Irene M ^a   Kreiner, Gerhard ^a   Christ, Guenter ^a   Jilma, Bernd ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; ESOMEPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ADULT; AGED; ARTICLE; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG INHIBITION; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY INDEX; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SCORING SYSTEM; THROMBOCYTE; THROMBOCYTE AGGREGATION;

EID: 57149104093     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.09.017     Document Type: Article

References (32)

1. Snoep J.D., Hovens M.M., Eikenboom J.C., et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 154 (2007) 221-231
2. Siller-Matula J., Schror K., Wojta J., et al. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost 97 (2007) 385-393
3. Angiolillo D.J., Guzman L.A., and Bass T.A. Current antiplatelet therapies: benefits and limitations. Am Heart J 156 (2008) S3-S9
4. Gladding P., Webster M., Ormiston J., et al. Antiplatelet drug nonresponsiveness. Am Heart J 155 (2008) 591-599
5. Savi P., Pereillo J.M., Uzabiaga M.F., et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 84 (2000) 891-896
6. Pereillo J.M., Maftouh M., Andrieu A., et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 30 (2002) 1288-1295
7. Small D.S., Farid N.A., Payne C.D., et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 48 (2008) 475-484
8. Lotfi A., Schweiger M.J., Giugliano G.R., et al. High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients-a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis. Am Heart J 155 (2008) 954-958
9. Li X.Q., Andersson T.B., Ahlstrom M., et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 32 (2004) 821-827
10. Gilard M., Arnaud B., Cornily J.C., et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 51 (2008) 256-260
11. Gilard M., Arnaud B., Le Gal G., et al. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 4 (2006) 2508-2509
12. Ishizaki T., and Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther 13 Suppl 3 (1999) 27-36
13. Cairns J.A., and Eikelboom J. Clopidogrel resistance: more grist for the mill. J Am Coll Cardiol 51 (2008) 1935-1937
14. Gurbel P.A., Becker R.C., Mann K.G., et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 50 (2007) 1822-1834
15. Manolopoulos P., Glenn J.R., Fox S.C., et al. Acyl derivatives of coenzyme A inhibit platelet function via antagonism at P2Y1 and P2Y12 receptors: a new finding that may influence the design of anti-thrombotic agents. Platelets 19 (2008) 134-145
16. Sudo T., Ito H., and Kimura Y. Phosphorylation of the vasodilator-stimulated phosphoprotein (VASP) by the anti-platelet drug, cilostazol, in platelets. Platelets 14 (2003) 381-390
17. Judge H.M., Buckland R.J., Sugidachi A., et al. The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses. Platelets 19 (2008) 125-133
18. Bonello L., Paganelli F., Arpin-Bornet M., et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 5 (2007) 1630-1636
19. Bonello L., Camoin-Jau L., Arques S., et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 51 (2008) 1404-1411
20. Kleiman N.S. Will measuring vasodilator-stimulated phosphoprotein phosphorylation help us optimize the loading dose of clopidogrel?. J Am Coll Cardiol 51 (2008) 1412-1414
21. Siller-Matula J., Lang I., Christ G., et al. Calcium channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 52 (2008) 1557-1563
22. Siller-Matula J.M., Panzer S., and Jilma B. Reproducibility and standardised reporting of the vasodilator-stimulated phosphoprotein phosphorylation assay. Platelets 19 (2008) 551-554
23. Morel O., Faure A., Ohlmann P., et al. Impaired platelet responsiveness to clopidogrel identified by flow cytometric vasodilator-stimulated phosphoprotein (VASP) phosphorylation in patients with subacute stent thrombosis. Thromb. Haemost. 98 (2007) 896-899
24. Seyfert U.T., Haubelt H., Vogt A., et al. Variables influencing Multiplate (TM) whole blood impedance platelet aggregometry and turbidimetric platelet aggregation in healthy individuals. Platelets 18 (2007) 199-206
25. Sibbing D., Braun S., Jawansky S., et al. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost 99 (2008) 121-126
26. Toth O., Calatzis A., Penz S., et al. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 96 (2006) 781-788
27. Penz S.M., Reininger A.J., Toth O., et al. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques. Thromb Haemost 97 (2007) 435-443
28. Mueller T., Dieplinger B., Poelz W., et al. Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel Multiplate(R) analyzer-comparison with two flow cytometric methods. Thromb Res 121 (2007) 249-258
29. Abelo A., Andersson T.B., Antonsson M., Naudot A.K., Skanberg I., and Weidolf L. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 28 (2000) 966-972
30. Lau W.C., Waskell L.A., Watkins P.B., et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 107 (2003) 32-37
31. Saw J., Brennan D.M., Steinhubl S.R., et al. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol 50 (2007) 291-295
32. Angiolillo D.J., and Alfonso F. Clopidogrel-statin interaction: myth or reality?. J Am Coll Cardiol 50 (2007) 296-298